INmune Bio(INMB) - 2024 Q4 - Annual Results

Exhibit 99.1 CORDStrom™ Platform INKmune® Platform: 2 ● Reported results of a double-blinded, randomized, placebo-controlled, cross-over study, known as "MissionEB," investigating CORDStrom™ for treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) in pediatric patients, which evidenced a favorable benefit-risk profile. ● FDA granted CORDStrom™ a Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for treatment of epidermolysis bullosa (EB). ● Data from the MissionEB trial s ...